A comprehensive profiling of the immune microenvironment of breast cancer brain metastases

Abstract Background Despite potential clinical implications, the complexity of breast cancer (BC) brain metastases (BM) immune microenvironment is poorly understood. Through multiplex immunofluorescence, we here describe the main features of BCBM immune microenvironment (density and spatial distribution) and evaluate its prognostic impact. Methods Sixty BCBM from patients undergoing neurosurgery at three institutions (2003-2018) were comprehensively assessed using two multiplex immunofluorescence panels (CD4, CD8, Granzyme B, FoxP3, CD68, pan-cytokeratin, DAPI; CD3, PD-1, PD-L1, LAG-3, TIM-3, CD163, pan-cytokeratin, DAPI). The prognostic impact of immune subpopulations and cell-to-cell spatial interactions was evaluated. Results Subtype-related differences in BCBM immune microenvironment and its prognostic impact were observed. While in HR−/HER2− BM and HER2+ BM, higher densities of intra-tumoral CD8+ lymphocytes were associated with significantly longer OS (HR 0.16 and 0.20, respectively), in HR+/HER2− BCBMs a higher CD4+FoxP3+/CD8+ cell ratio in the stroma was associated with worse OS (HR 5.4). Moreover, a higher density of intra-tumoral CD163+ M2-polarized microglia/macrophages in BCBMs was significantly associated with worse OS in HR−/HER2− and HR+/HER2− BCBMs (HR 6.56 and 4.68, respectively), but not in HER2+ BCBMs. In HER2+ BCBMs, multiplex immunofluorescence highlighted a negative prognostic role of PD-1/PD-L1 interaction: patients with a higher percentage of PD-L1+ cells spatially interacting with (within a 20 µm radius) PD-1+ cells presented a significantly worse OS (HR 4.60). Conclusions Our results highlight subtype-related differences in BCBM immune microenvironment and identify two potential therapeutic targets, M2 microglia/macrophage polarization in HER2− and PD-1/PD-L1 interaction in HER2+ BCBMs, which warrant future exploration in clinical trials.

[1]  M. Timmermans,et al.  Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer , 2021, Nature Communications.

[2]  V. Ozmen,et al.  TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer , 2021, BMC Cancer.

[3]  P. Nuciforo,et al.  Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer , 2021, npj Precision Oncology.

[4]  B. Yao,et al.  TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation , 2021, Frontiers in Oncology.

[5]  L. Cavanna,et al.  Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer , 2021, NPJ breast cancer.

[6]  C. Anders,et al.  Salting the Soil: Targeting the Microenvironment of Brain Metastases , 2021, Molecular Cancer Therapeutics.

[7]  M. Dieci,et al.  Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. , 2020, European journal of cancer.

[8]  A. Anderson,et al.  Tim-3 finds its place in the cancer immunotherapy landscape , 2020, Journal for immunotherapy of cancer.

[9]  B. Kamińska,et al.  Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions , 2020, Theranostics.

[10]  Marimuthu Citartan,et al.  Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice , 2020, Frontiers in Oncology.

[11]  M. Campone,et al.  Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort , 2019, British Journal of Cancer.

[12]  Guangzhe Zhao,et al.  Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival , 2019, International journal of cancer.

[13]  Sanpreet Singh,et al.  Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity , 2019, Cancer Immunology, Immunotherapy.

[14]  A. Vincent-Salomon,et al.  Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy , 2019, Clinical Cancer Research.

[15]  H. van Eenennaam,et al.  Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy , 2019, Oncoimmunology.

[16]  B. Kamińska,et al.  Immune Microenvironment of Brain Metastases—Are Microglia and Other Brain Macrophages Little Helpers? , 2019, Front. Immunol..

[17]  M. Dieci,et al.  Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer , 2019, Journal of Immunotherapy for Cancer.

[18]  A. Giobbie-Hurder,et al.  Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. , 2019, The Lancet. Oncology.

[19]  George C. Tseng,et al.  Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors , 2019, Journal of Immunotherapy for Cancer.

[20]  Heikki Joensuu,et al.  Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Carey,et al.  Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases , 2019, Breast Cancer Research and Treatment.

[22]  S. Wiemann,et al.  PI3K: A master regulator of brain metastasis‐promoting macrophages/microglia , 2018, Glia.

[23]  S. Leung,et al.  TIM-3 expression in breast cancer , 2018, Oncoimmunology.

[24]  M. Dieci,et al.  Immune characterization of breast cancer metastases: prognostic implications , 2018, Breast Cancer Research.

[25]  T. Nielsen,et al.  Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. , 2017, Seminars in cancer biology.

[26]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[27]  P. Nuciforo,et al.  A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  N. Sibson,et al.  Anti-inflammatory Microglia/Macrophages As a Potential Therapeutic Target in Brain Metastasis , 2017, Front. Oncol..

[29]  H. Iwata,et al.  Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer , 2017, Oncotarget.

[30]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[31]  Souptik Barua,et al.  Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer , 2017, Nature Communications.

[32]  P. Brastianos,et al.  Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. , 2017, CNS oncology.

[33]  P. Walker,et al.  Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? , 2016, Front. Oncol..

[34]  Su Jin Heo,et al.  PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients , 2016, Scientific Reports.

[35]  S. Loi,et al.  The genomic landscape of breast cancer and its interaction with host immunity. , 2016, Breast.

[36]  M. Dieci,et al.  The immune system and hormone-receptor positive breast cancer: Is it really a dead end? , 2016, Cancer treatment reviews.

[37]  S. Loi,et al.  Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis , 2016, Breast Cancer Research.

[38]  H. Heinzl,et al.  Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases , 2016, Oncoimmunology.

[39]  Bernard A. Fox,et al.  Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma , 2015, Journal of Immunotherapy for Cancer.

[40]  B. Bender,et al.  Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases , 2015, Oncotarget.

[41]  J. Taube,et al.  Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma , 2015, Oncoimmunology.

[42]  Hyung-Seok Kim,et al.  The HIF-1/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia , 2015, Nature Communications.

[43]  Chichung Wang,et al.  Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.

[44]  L. Gianni,et al.  The immune system and response to HER2-targeted treatment in breast cancer. , 2014, The Lancet. Oncology.

[45]  Yan Li,et al.  Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells , 2013, Front. Immunol..

[46]  S. Moestrup,et al.  CD163 and inflammation: biological, diagnostic, and therapeutic aspects. , 2013, Antioxidants & redox signaling.

[47]  V. Kuchroo,et al.  The costimulatory role of TIM molecules , 2009, Immunological reviews.

[48]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  E. Winer,et al.  Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma , 2003, Cancer.